Literature DB >> 6340204

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.

C Myers, R Bonow, S Palmeri, J Jenkins, B Corden, G Locker, J Doroshow, S Epstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6340204

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  52 in total

1.  Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.

Authors:  G Minotti; C Mancuso; A Frustaci; A Mordente; S A Santini; A M Calafiore; G Liberi; N Gentiloni
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 2.  Heart Failure in Relation to Anthracyclines and Other Chemotherapies.

Authors:  Tolulope A Agunbiade; Raja Y Zaghlol; Ana Barac
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 3.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

4.  Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.

Authors:  Joy Marie Fulbright; Daniela E Egas-Bejar; Winston W Huh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2015-10-29       Impact factor: 3.333

Review 5.  Chemotherapy-induced cardiotoxicity.

Authors:  Amir Y Shaikh; Jeffrey A Shih
Journal:  Curr Heart Fail Rep       Date:  2012-06

6.  Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction.

Authors:  Laura A A Gilliam; Daniel S Lark; Lauren R Reese; Maria J Torres; Terence E Ryan; Chien-Te Lin; Brook L Cathey; P Darrell Neufer
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-06-21       Impact factor: 4.310

7.  Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death.

Authors:  Satoru Kobayashi; Paul Volden; Derek Timm; Kai Mao; Xianmin Xu; Qiangrong Liang
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

8.  Ozone-Oxidative Preconditioning Prevents Doxorubicin-induced Cardiotoxicity in Sprague-Dawley Rats.

Authors:  Livan Delgado-Roche; Yanet Hernández-Matos; Emilio A Medina; Dalia Á Morejón; Maité R González; Gregorio Martínez-Sánchez
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24

Review 9.  Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.

Authors:  Lesley A Smith; Victoria R Cornelius; Christopher J Plummer; Gill Levitt; Mark Verrill; Peter Canney; Alison Jones
Journal:  BMC Cancer       Date:  2010-06-29       Impact factor: 4.430

10.  Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

Authors:  O Popelová; M Sterba; P Hasková; T Simůnek; M Hroch; I Guncová; P Nachtigal; M Adamcová; V Gersl; Y Mazurová
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.